Search
gefapixant
Indications:
- chronic cough
* FDA rejects approval, benefit not clinically meaningful
Dosage:
- 45 mg PO BID Adverese effects:
- taste disturbance
Mechanism of action:
- P2X3 antagonist
Clinical trials:
- in phase 3 trial
Interactions
drug adverse effects of antitussive agent(s)
General
antitussive agent
Database Correlations
PUBCHEM cid=24764487
References
- Boyles S
Gefapixant Reduces Chronic Cough in Phase III Trials -
But taste distortion was frequent AE at active dosage.
MedPage Today September 9, 2020
https://www.medpagetoday.com/meetingcoverage/ers/88515
- Short E
Drug Candidate for Chronic Cough Rejected by FDA Panel.
Gefapixant's benefit not clinically meaningful enough, panelists say
MedPage Today November 17, 2023
https://www.medpagetoday.com/pulmonology/generalpulmonary/107440